Nonsquamous Nonsmall Cell Neoplasm of Lung Clinical Trial
Official title:
A 2-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo Versus Carboplatin, Pemetrexed Plus Truncated Demcizumab as First-Line Treatment in Subjects With Stage IV Non-Squamous Non-Small Cell Lung Cancer
A randomized, double-blind, 3-arm (1:1:1) study in subjects with first-line Stage IV non-squamous NSCLC. The purpose is to test the efficacy and safety of demcizumab, when given in combination with carboplatin and pemetrexed compared to placebo. The administration of carboplatin and pemetrexed is a standard treatment for patients with non-squamous non-small cell lung cancer.
Patients will be enrolled at centers in North America, Western Europe, Australia and New
Zealand. Up to 28 days (4 weeks) prior to treatment.
If enrolled in the study, you will receive intravenous (in the vein) infusions of demcizumab
(or placebo), carboplatin, and pemetrexed administered on the same day, every 21 days for 4
cycles, or until it has been shown that your cancer has gotten worse. If your physician
decides to delay treatment with one of the agents due to side effects, the other agents may
still be administered as scheduled. After 4 cycles, if you have stable or improved disease,
you will continue to receive pemetrexed once every 21 days as maintenance therapy. After 8
cycles, if you have stable or improved disease, you may receive demcizumab (or placebo),
every 21 days for 4 more cycles.
You will undergo assessments every 6 weeks to determine the status of your disease.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03380871 -
A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer
|
Phase 1 | |
| Terminated |
NCT01373463 -
Cisplatin and Pemetrexed With Radiation Followed by Lobectomy
|
Phase 1 | |
| Completed |
NCT02679443 -
Vitamin Supplementation in NSCLC Patients on Pemetrexed Based Chemotherapy
|
N/A | |
| Not yet recruiting |
NCT05764928 -
Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy
|
Phase 1/Phase 2 | |
| Completed |
NCT02049060 -
Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin
|
Phase 1/Phase 2 | |
| Completed |
NCT01814163 -
Observational Post-authorization Studies Carboplatin, Paclitaxel and Bevacizumab
|
N/A | |
| Terminated |
NCT02831933 -
Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma
|
Phase 2 | |
| Terminated |
NCT02019979 -
Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC)
|
Phase 2 | |
| Completed |
NCT01705184 -
Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer.
|
Phase 2 | |
| Not yet recruiting |
NCT02852798 -
Apatinib Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR WT, Non-squamous NSCLC
|
N/A | |
| Active, not recruiting |
NCT03846310 -
A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer
|
Phase 1 |